COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
26 oct. 2022 16h00 HE
|
COMPASS Pathways
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
12 oct. 2022 11h00 HE
|
COMPASS Pathways
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
04 oct. 2022 09h05 HE
|
COMPASS Pathways
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
19 sept. 2022 16h01 HE
|
COMPASS Pathways
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in three upcoming investor events
01 sept. 2022 08h06 HE
|
COMPASS Pathways
LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
04 août 2022 07h00 HE
|
COMPASS Pathways
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in...
COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
02 août 2022 16h05 HE
|
COMPASS Pathways
LONDON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference
01 août 2022 08h00 HE
|
COMPASS Pathways
LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
28 juil. 2022 04h00 HE
|
COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
26 juil. 2022 08h00 HE
|
COMPASS Pathways
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...